https://www.nasdaq.com/press-release/biohaven-and-pfizer-complete-collaboration-transaction-for-commercialization-of
https://www.nasdaq.com/press-release/biohaven-announces-nurtecr-odt-receives-first-global-approval-outside-the-u.s.-for
https://www.nasdaq.com/press-release/biohaven-reports-positive-topline-results-from-pivotal-migraine-trial-of-intranasal
https://www.nasdaq.com/press-release/biohaven-names-ceo-vlad-coric-md-chairman-of-the-board-of-directors-and-matthew-buten
https://www.nasdaq.com/press-release/artizan-biosciences-and-biohaven-therapeutics-announce-therapeutic-development
https://www.nasdaq.com/press-release/nurtecr-odt-approved-in-kuwait-for-acute-treatment-of-migraine-2021-11-17
https://www.nasdaq.com/press-release/biohaven-completes-enrollment-of-verdiperstat-arm-of-pivotal-healey-als-platform
https://www.nasdaq.com/press-release/biohaven-and-pfizer-enter-strategic-collaboration-for-the-commercialization-of
https://www.nasdaq.com/press-release/biohaven-reports-third-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohaven-to-report-third-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/nine-line-apparel-and-biohavens-nurtec-odt-set-to-honor-world-war-ii-veterans-ahead
https://www.nasdaq.com/press-release/biohaven-enrolls-phase-1a-1b-clinical-trial-of-bhv-1100-lead-asset-from-its-armtm
https://www.nasdaq.com/press-release/biohaven-announces-preliminary-3q2021-net-product-revenue-for-nurtec-odt-the-first
https://www.nasdaq.com/press-release/biohaven-provides-update-on-phase-3-trial-and-multiple-system-atrophy-msa-program
https://www.nasdaq.com/press-release/biohaven-spotlights-nurtecr-odt-rimegepant-the-only-dual-therapy-indicated-for-both
https://www.nasdaq.com/press-release/biohaven-reports-second-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohavens-nurtecr-odt-signs-as-official-migraine-partner-of-big-machine-music-city
https://www.nasdaq.com/press-release/biohaven-to-report-second-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohaven-announces-preliminary-2q2021-net-product-revenue-for-nurtec-odt-the-first
https://www.nasdaq.com/press-release/sosei-heptares-initiates-phase-1-trial-with-novel-small-molecule-cgrp-antagonist
https://www.nasdaq.com/press-release/biohaven-appoints-kishen-mehta-to-board-of-directors-2021-06-17
https://www.nasdaq.com/press-release/photo-of-biohaven-pharmaceuticals-ringing-the-opening-bell-available-on-business
https://www.nasdaq.com/press-release/biohaven-showcases-cgrp-antagonist-franchise-data-including-nurtecr-odt-rimegepant
https://www.nasdaq.com/press-release/fda-approves-biohavens-nurtecr-odt-rimegepant-for-prevention%3a-now-the-first-and-only
https://www.nasdaq.com/press-release/biohavens-nurtecr-odt-signs-as-primary-partner-with-rick-ware-racing-for-2021-ntt
https://www.nasdaq.com/press-release/national-headache-foundation-survey-shows-majority-of-people-with-migraine-are-unable
https://www.nasdaq.com/press-release/c-o-r-r-e-c-t-i-o-n-biohaven-pharmaceutical-holding-company-ltd.-2021-05-10
https://www.nasdaq.com/press-release/biohaven-to-report-first-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohaven-highlights-neuroscience-advancements-with-22-presentations-at-the-2021
https://www.nasdaq.com/press-release/biohaven-announces-preliminary-1q2021-net-product-revenue-for-nurtec-odt-2021-04-07
https://www.nasdaq.com/press-release/rick-ware-racing-biohavens-nurtec-odt-and-nine-line-apparel-honor-fallen-service
https://www.nasdaq.com/press-release/biohaven-enrolls-first-patient-in-phase-2-3-trial-of-oral-zavegepant-prompting-%24100
https://www.nasdaq.com/press-release/biohaven-announces-pricing-of-%24200-million-public-offering-of-common-shares-2021-03
https://www.nasdaq.com/press-release/biohaven-announces-proposed-public-offering-of-common-shares-2021-03-15
https://www.nasdaq.com/press-release/biohavens-nurtecr-odt-approved-in-united-arab-emirates-for-acute-treatment-of
https://www.nasdaq.com/press-release/biohaven-announces-completion-of-50-enrollment-ahead-of-timelines-in-verdiperstat
https://www.nasdaq.com/press-release/biohavens-nurtecr-odt-approved-in-israel-for-acute-treatment-of-migraine-2021-03-10
https://www.nasdaq.com/press-release/artizan-biosciences-closes-%2411-million-series-a-2-financing-and-enters-option-and
https://www.nasdaq.com/press-release/biohaven-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/biohaven-to-report-fourth-quarter-and-full-year-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/biohavens-bhv-1200-a-multimodal-antibody-therapy-enhancer-mate-demonstrates-effective
https://www.nasdaq.com/press-release/biohaven-provides-update-on-esg-practices-2021-02-08
https://www.nasdaq.com/press-release/biohaven-announces-preliminary-4q2020-net-product-revenue-for-nurtecr-odt-2021-01-25
https://www.nasdaq.com/press-release/biohaven-signs-cody-ware-as-driver-for-nurtecr-odt-chevrolet-for-the-2021-nascar-cup
https://www.nasdaq.com/press-release/biohaven-provides-update-on-phase-2-3-trial-and-alzheimers-disease-program-2021-01-18
https://www.nasdaq.com/press-release/biohaven-acquires-kleo-pharmaceuticals-and-licenses-platform-technology-from-yale
https://www.nasdaq.com/press-release/biohavens-nurtecr-odt-partners-with-rick-ware-racing-for-24-hours-of-daytona-entry
https://www.nasdaq.com/press-release/biohaven-begins-pivotal-phase-3-trial-of-troriluzole-in-obsessive-compulsive-disorder
https://www.nasdaq.com/press-release/biohavens-rimegepant-for-preventive-treatment-of-migraine-published-in-the-lancet
https://www.nasdaq.com/press-release/biohavens-nurtectm-odt-partners-with-the-rick-ware-racing-team-in-the-2021-nascar-cup
https://www.nasdaq.com/press-release/sosei-heptares-and-biohaven-enter-global-collaboration-and-license-agreement-to
https://www.nasdaq.com/press-release/value-based-agreement-between-prime-therapeutics-and-biohaven-aims-to-bring-nurtectm
https://www.nasdaq.com/press-release/biohaven-pharmaceuticals-and-weill-cornell-medicine-collaborate-to-initiate-proof-of
https://www.nasdaq.com/press-release/biohaven-pharmaceuticals-inaugural-partner-of-national-ataxia-foundations-drug
https://www.nasdaq.com/press-release/biohaven-reports-third-quarter-2020-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohaven-to-report-third-quarter-2020-financial-results-and-recent-business
https://www.nasdaq.com/press-release/u.s.-fda-accepts-biohavens-supplemental-new-drug-application-snda-of-nurtectm-odt-for
https://www.nasdaq.com/press-release/bioshin-biohavens-asia-pacific-subsidiary-raises-%2460m-in-series-a-funding-to-advance
https://www.nasdaq.com/press-release/biohavens-oral-zavegepant-a-third-generation-cgrp-receptor-antagonist-receives
https://www.nasdaq.com/press-release/biohaven-reports-second-quarter-2020-financial-results-and-recent-business
https://www.nasdaq.com/press-release/biohaven-announces-up-to-%24500-million-non-dilutive-term-loan-with-sixth-street-2020
https://www.nasdaq.com/press-release/biohaven-and-royalty-pharma-announce-funding-agreement-totaling-up-to-%24450-million
https://www.nasdaq.com/press-release/biohaven-and-royalty-pharma-announce-funding-agreement-totaling-up-to-%24450-million-0
https://www.nasdaq.com/press-release/biohaven-pharmaceutical-to-report-second-quarter-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/biohaven-announces-enrollment-of-first-patients-in-pivotal-healey-als-platform-trial
https://www.nasdaq.com/press-release/biohaven-completes-enrollment-ahead-of-timelines-in-international-phase-3-clinical
https://www.nasdaq.com/press-release/after-living-with-migraine-for-years-khloe-kardashian-leads-biohavens-take-back-today
https://www.nasdaq.com/press-release/biohaven-announces-obsessive-compulsive-disorder-ocd-proof-of-concept-phase-2-3-study
https://www.nasdaq.com/press-release/biohaven-presents-nurtectm-rimegepant-clinical-and-pharmacoeconomic-data-at-the
https://www.nasdaq.com/press-release/biohaven-appoints-bob-hugin-to-its-board-of-directors-2020-06-10
https://www.nasdaq.com/press-release/biohaven-showcases-clinical-and-pharmacoeconomic-data-for-nurtectm-odt-rimegepant
https://www.nasdaq.com/press-release/biohaven-pharmaceuticals-reports-first-quarter-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/biohaven-enters-into-agreement-with-genpharm-for-distribution-of-nurtectm-odt-in-the
https://www.nasdaq.com/press-release/biohaven-changing-2020-annual-meeting-of-shareholders-to-virtual-only-meeting-format
https://www.nasdaq.com/press-release/biohaven-enters-into-partnership-with-medison-pharma-to-distribute-nurtectm-odt-in
https://www.nasdaq.com/press-release/biohaven-receives-fda-may-proceed-letter-to-begin-phase-2-trial-of-intranasal
https://www.nasdaq.com/press-release/biohaven-enters-into-collaboration-with-cove-leading-migraine-telemedicine-platform
https://www.nasdaq.com/press-release/biohaven-achieves-positive-results-in-pivotal-trial-of-oral-nurtectm-dosed-every
https://www.nasdaq.com/press-release/biohaven-to-advance-vazegepant-into-phase-3-for-the-acute-treatment-of-migraine
https://www.nasdaq.com/press-release/biohavens-verdiperstat-receives-fast-track-designation-for-the-treatment-of-multiple
https://www.nasdaq.com/press-release/biohaven-announces-patient-savings-program-where-patients-can-pay-as-little-as-%240-for
https://www.nasdaq.com/press-release/biohavens-nurtectm-odt-rimegepant-75mg-is-now-available-in-u.s.-pharmacies-for-the
https://www.nasdaq.com/press-release/biohavens-nurtectm-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of
https://www.nasdaq.com/press-release/biohaven-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/biohavens-rimegepant-named-to-cortellis-2020-potential-blockbuster-drugs-to-watch
https://www.nasdaq.com/press-release/biohavens-troriluzole-study-for-generalized-anxiety-disorder-gad-misses-primary
https://www.nasdaq.com/press-release/biohaven-appoints-michael-heffernan-to-board-of-directors-2020-01-31
https://www.nasdaq.com/press-release/biohaven-announces-pricing-of-%24250-million-public-offering-of-common-shares-2020-01
https://www.nasdaq.com/press-release/biohaven-announces-proposed-public-offering-of-common-shares-2020-01-28
https://www.nasdaq.com/press-release/biohavens-verdiperstat-receives-fda-may-proceed-letter-to-initiate-trial-in
https://www.nasdaq.com/press-release/biohavens-troriluzole-successfully-advances-past-interim-futility-analysis-in-pivotal
https://www.nasdaq.com/press-release/biohaven-announces-issuance-of-composition-of-matter-patent-on-troriluzole-by-the-u.s
https://www.nasdaq.com/press-release/kleo-pharmaceuticals-to-present-at-piper-jaffray-31st-annual-healthcare-conference
https://www.nasdaq.com/press-release/kleo-pharmaceuticals-presents-preclinical-data-supporting-development-of-its-cd38
https://www.nasdaq.com/press-release/biohaven-completes-enrollment-in-pivotal-phase-2-3-alzheimers-disease-clinical-trial
https://www.nasdaq.com/press-release/biohaven-statement-regarding-kleo-pharmaceuticals-kleo%3a-thomas-j.-lynch-jr.-md
